Table 1.

The clinical characteristics of patients with NCPH or portal obstruction/stenosis caused by systemic vasculitis.

References	Gender/age	Etiology	Manifestation	PVT	NCPH	Treatment	improvement after Treatment
Wolf et al. (11)	F/36	EGPA	Necrotic skin lesions, pulmonary infiltrates, right upper quadrant tenderness	Yes	No	Prednisolone 60 mg qd., low molecular weight heparin, methotrexate	Yes
Natarajan et al. (12)	M/48	Churg-Strauss disease	Abdominal distension, fever, ascites, abdominal wall varices	Yes	Yes	Dexamethasone 6 mg tid., tapering dose of prednisolone 1 mg/kg/day, warfarin 3 mg qd.	Yes
Herrera et al. (13)	M/9	TA	Recurrent fever, hepatosplenomegaly	No	Yes	Methylprednisolone followed by prednisone, cyclophosphamide, azathioprine, infliximab	No
Abebe et al. (14)	M/58	HSP	Rash, nausea, vomiting, abdominal pain, dark stool, hematochezia	Yes	NA	Methylprednisolone 1 g qd. followed by 30 mg q12h.	No
Gelber et al. (15)	M/22	Behçet’s Disease	Fever, abdominal pain, weight loss, diarrhea	Yes	NA	NA	NA
Nakazawa et al. (16)	M/73	PN	Intermittent fever, abdominal pain, erythema, and myalgia	No, just narrowing of the portal vein	NA	Prednisolone 30 mg/day	No

PVT, portal venous thrombosis; NCPH, non-cirrhotic portal hypertension; EGPA, eosinophilic granulomatosis with polyangiitis; TA, Takayasu arteritis; HSP, Henoch Schonlein purpura; PN, Polyarteritis nodosa; NA, not available.